Skip to main content
Top
Published in: Annals of Surgical Oncology 10/2011

01-10-2011 | Breast Oncology

Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference

Authors: Masakazu Toi, MD, Eric P. Winer, MD, Takashi Inamoto, MD, John R. Benson, MD, John F. Forbes, MD, Michihide Mitsumori, MD, John F. R. Robertson, MD, Hironobu Sasano, MD, Gunter von Minckwitz, MD, Akira Yamauchi, MD, V. Suzanne Klimberg, MD

Published in: Annals of Surgical Oncology | Issue 10/2011

Login to get access

Abstract

A consensus conference was held to investigate issues related to the local management of early breast cancer. Here, we highlight the major topics discussed at the conference and propose ideas for future studies. Regarding axillary management, we examined three major issues. First, we discussed whether the use of axillary reverse mapping could clarify the lymphatic system of breast and whether the ipsilateral arm might help avoid lymphedema. Second, the use of an indocyanine green fluorescent navigation system was discussed for intraoperative lymphatic mapping. These new issues should be examined further in practice. Finally, some agreement was reached on the importance of “four-node diagnosis” to aid in the diagnostic accuracy of sentinel nodes. Regarding breast treatment, there was general agreement that the clinical value of surgical margins in predicting local failure was dependent on the tumor’s intrinsic biology and subtypes. For patients treated with preoperative chemotherapy, less extensive excision may be feasible in those who respond to systemic therapy in an acceptable manner. Most trials of preoperative chemotherapy lack outcome data on local recurrence. Therefore, there is a need for such data for overview analysis. We also agreed that radiation after mastectomy may be beneficial in node-positive cases where more than four nodes are involved. Throughout the discussions for both invasive and noninvasive disease, the investigation of nomograms was justified for major issues in the decision-making process, such as the presence or absence of microinvasion and the involvement of nonsentinel nodes in sentinel node-positive patients.
Literature
1.
go back to reference de Mascarel I, Macgrogan G, Deblet M, et al. Distinction between isolated tumor cells and micrometastasis in breast cancer. Cancer. 2008;112:1672–8.PubMedCrossRef de Mascarel I, Macgrogan G, Deblet M, et al. Distinction between isolated tumor cells and micrometastasis in breast cancer. Cancer. 2008;112:1672–8.PubMedCrossRef
2.
go back to reference Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.PubMedCrossRef Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.PubMedCrossRef
3.
go back to reference Clarke D, Khonji N, Mansel R. Sentinel node biopsy in breast cancer: ALMANC trial. World J Surg. 2001;25;819–22.PubMedCrossRef Clarke D, Khonji N, Mansel R. Sentinel node biopsy in breast cancer: ALMANC trial. World J Surg. 2001;25;819–22.PubMedCrossRef
4.
go back to reference Boneti C, Korourian S, Bland K, et al. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy. J Am Coll Surg. 2008;206:1038–44.PubMedCrossRef Boneti C, Korourian S, Bland K, et al. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy. J Am Coll Surg. 2008;206:1038–44.PubMedCrossRef
5.
go back to reference Kitai T, Inomoto T, Miwa M, et al. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211–15.PubMedCrossRef Kitai T, Inomoto T, Miwa M, et al. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005;12:211–15.PubMedCrossRef
6.
go back to reference Yi M, Meric-Bernstam F, Ross MI, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008;113:30–7.PubMedCrossRef Yi M, Meric-Bernstam F, Ross MI, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer. 2008;113:30–7.PubMedCrossRef
7.
go back to reference Dabbs DJ, Johnson R. The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J. 2004;10:186–9.PubMedCrossRef Dabbs DJ, Johnson R. The optimal number of sentinel lymph nodes for focused pathologic examination. Breast J. 2004;10:186–9.PubMedCrossRef
8.
go back to reference Zavagno G, De Salvo GL, Bozza F, et al. Number of metastatic sentinel lymph nodes as predictor of axillary involvement in patients with breast cancer. Breast Cancer Res Treat. 2004;86:171–9.PubMedCrossRef Zavagno G, De Salvo GL, Bozza F, et al. Number of metastatic sentinel lymph nodes as predictor of axillary involvement in patients with breast cancer. Breast Cancer Res Treat. 2004;86:171–9.PubMedCrossRef
9.
go back to reference Barranger E, Coutant C, Flahault A, et al. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91:113–9.PubMedCrossRef Barranger E, Coutant C, Flahault A, et al. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91:113–9.PubMedCrossRef
10.
go back to reference Boileau JF, Easson A, Escallon JM, et al. Sentinel nodes in breast cancer: relevance of axillary level II nodes and optimal number of nodes that need to be removed. Ann Surg Oncol. 2008;15:1710–6.PubMedCrossRef Boileau JF, Easson A, Escallon JM, et al. Sentinel nodes in breast cancer: relevance of axillary level II nodes and optimal number of nodes that need to be removed. Ann Surg Oncol. 2008;15:1710–6.PubMedCrossRef
11.
go back to reference Rubio I, Pedreira F, Roca I, et al. Removal of all radioactive sentinel nodes in breast cancer improves the detection of positive sentinel nodes. Clin Transl Oncol. 2008;10:347–50.PubMedCrossRef Rubio I, Pedreira F, Roca I, et al. Removal of all radioactive sentinel nodes in breast cancer improves the detection of positive sentinel nodes. Clin Transl Oncol. 2008;10:347–50.PubMedCrossRef
12.
go back to reference Veronesi U, Galimberti V, Paganelli G, et al. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer. 2009;45:1381–8.PubMedCrossRef Veronesi U, Galimberti V, Paganelli G, et al. Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases. Eur J Cancer. 2009;45:1381–8.PubMedCrossRef
13.
go back to reference Layeequr Rahman R, Siegel E, Boneti C, et al. Stage migration with sentinel node biopsy in breast cancer. Am J Surg. 2009;197:491–6.PubMedCrossRef Layeequr Rahman R, Siegel E, Boneti C, et al. Stage migration with sentinel node biopsy in breast cancer. Am J Surg. 2009;197:491–6.PubMedCrossRef
14.
go back to reference Benson JR, della Rovere GQ; Axilla Management Consensus Group. Management of the axilla in women with breast cancer. Lancet Oncol. 2007;8:331–48.PubMedCrossRef Benson JR, della Rovere GQ; Axilla Management Consensus Group. Management of the axilla in women with breast cancer. Lancet Oncol. 2007;8:331–48.PubMedCrossRef
15.
go back to reference Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694–702.PubMedCrossRef Mamounas EP, Brown A, Anderson S, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23:2694–702.PubMedCrossRef
16.
go back to reference Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg. 2008;247:315–9.PubMedCrossRef Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European institute of oncology on 854 patients in 10 years. Ann Surg. 2008;247:315–9.PubMedCrossRef
17.
go back to reference Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol. 2007;14:2202–8.PubMedCrossRef Julian TB, Land SR, Fourchotte V, et al. Is sentinel node biopsy necessary in conservatively treated DCIS? Ann Surg Oncol. 2007;14:2202–8.PubMedCrossRef
18.
go back to reference Katz A, Smith BL, Golshan M, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol. 2008;26:2093–8.PubMedCrossRef Katz A, Smith BL, Golshan M, et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol. 2008;26:2093–8.PubMedCrossRef
19.
go back to reference Morrow M. Trends in the surgical treatment of breast cancer. Breast J. 2010;16(Suppl 1):17–9.CrossRef Morrow M. Trends in the surgical treatment of breast cancer. Breast J. 2010;16(Suppl 1):17–9.CrossRef
20.
go back to reference Sabel MS. Surgical considerations in early-stage breast cancer: Lessons learned and future directions. Semin Radiat Oncol. 2011;21:10–9.PubMedCrossRef Sabel MS. Surgical considerations in early-stage breast cancer: Lessons learned and future directions. Semin Radiat Oncol. 2011;21:10–9.PubMedCrossRef
21.
go back to reference Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med. 2002;347:1233–41.CrossRef Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med. 2002;347:1233–41.CrossRef
22.
go back to reference Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMed Clarke M, Collins R, Darby S, et al. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.PubMed
23.
go back to reference Nguyen PL, TaghianAG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8.PubMedCrossRef Nguyen PL, TaghianAG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8.PubMedCrossRef
24.
go back to reference Romond EH, Perez EA,, Bryant J, et al. Trastruzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef Romond EH, Perez EA,, Bryant J, et al. Trastruzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.PubMedCrossRef
25.
go back to reference Komoike Y, Akiyama F, Iino Y, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer. 2006;106:35–41.PubMedCrossRef Komoike Y, Akiyama F, Iino Y, et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer. 2006;106:35–41.PubMedCrossRef
26.
go back to reference Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.PubMedCrossRef Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.PubMedCrossRef
27.
go back to reference Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15:21–33.PubMedCrossRef Fatouros M, Baltoyiannis G, Roukos DH. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol. 2008;15:21–33.PubMedCrossRef
28.
go back to reference Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol. 2009;16:1771–82.PubMedCrossRef Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol. 2009;16:1771–82.PubMedCrossRef
29.
go back to reference Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16:3380–7.PubMedCrossRef Garcia-Etienne CA, Barile M, Gentilini OD, et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16:3380–7.PubMedCrossRef
30.
go back to reference Bijker N, Meijnen P, Peters JL. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.PubMedCrossRef Bijker N, Meijnen P, Peters JL. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24:3381–7.PubMedCrossRef
31.
go back to reference Viani GA, Stefalo EJ, Afonso SL, et al. Breast-conserving surgery with or without radiotherapy in woman with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiation Oncol. 2007;2:28–39.CrossRef Viani GA, Stefalo EJ, Afonso SL, et al. Breast-conserving surgery with or without radiotherapy in woman with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiation Oncol. 2007;2:28–39.CrossRef
32.
go back to reference Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.PubMedCrossRef Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.PubMedCrossRef
33.
go back to reference Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615–20.PubMedCrossRef Dunne C, Burke JP, Morrow M, et al. Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol. 2009;27:1615–20.PubMedCrossRef
34.
go back to reference Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.PubMedCrossRef Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.PubMedCrossRef
35.
go back to reference Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–9.PubMedCrossRef Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–9.PubMedCrossRef
36.
go back to reference Forrest AP, Stewart HJ, Everington D, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet. 1996;348:708–13.PubMedCrossRef Forrest AP, Stewart HJ, Everington D, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet. 1996;348:708–13.PubMedCrossRef
37.
go back to reference Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963–70.PubMedCrossRef Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351:963–70.PubMedCrossRef
38.
go back to reference Lim M, Bellon JR, Gelman R, et al. A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. Int J Radiat Oncol Biol Phys. 2006;65:1149–54.PubMedCrossRef Lim M, Bellon JR, Gelman R, et al. A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer. Int J Radiat Oncol Biol Phys. 2006;65:1149–54.PubMedCrossRef
39.
go back to reference Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.PubMedCrossRef Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.PubMedCrossRef
40.
go back to reference Saverio SD, Catena F, Santini D, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008;109:405–16.PubMedCrossRef Saverio SD, Catena F, Santini D, et al. 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up. Breast Cancer Res Treat. 2008;109:405–16.PubMedCrossRef
41.
go back to reference Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–107.PubMedCrossRef Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371:1098–107.PubMedCrossRef
42.
go back to reference Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–50.PubMed Whelan T, MacKenzie R, Julian J, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94:1143–50.PubMed
43.
go back to reference Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259–65.PubMedCrossRef Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259–65.PubMedCrossRef
44.
go back to reference McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1004–9.PubMedCrossRef McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68:1004–9.PubMedCrossRef
45.
go back to reference Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22:4691–9.PubMedCrossRef Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;22:4691–9.PubMedCrossRef
46.
go back to reference O’Flynn EA, Morel JC, Gonzalez J, et al. Prediction of the presence of invasive disease from the measurement of extent of malignant microcalcification on mammography and ductal carcinoma in situ grade at core biopsy. Clin Radiol. 2009;64:178–83.PubMedCrossRef O’Flynn EA, Morel JC, Gonzalez J, et al. Prediction of the presence of invasive disease from the measurement of extent of malignant microcalcification on mammography and ductal carcinoma in situ grade at core biopsy. Clin Radiol. 2009;64:178–83.PubMedCrossRef
47.
go back to reference Colleoni M, Bagnardi V, Rotmensz N, et al. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol. 2009;20:1178–84.PubMedCrossRef Colleoni M, Bagnardi V, Rotmensz N, et al. A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer. Ann Oncol. 2009;20:1178–84.PubMedCrossRef
48.
go back to reference Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53.PubMedCrossRef Bilimoria KY, Bentrem DJ, Hansen NM, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27:2946–53.PubMedCrossRef
49.
go back to reference Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.PubMedCrossRef Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140–51.PubMedCrossRef
50.
go back to reference Gur AS, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg. 2009;208:229–35.PubMedCrossRef Gur AS, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg. 2009;208:229–35.PubMedCrossRef
51.
go back to reference Amanti C, Lombardi A, Maggi S, et al. Is complete axillary dissection necessary for all patients with positive findings on sentinel lymph node biopsy? Validation of a breast cancer nomogram for predicting the likelihood of a non-sentinel lymph node. Tumori. 2009;95:153–5.PubMed Amanti C, Lombardi A, Maggi S, et al. Is complete axillary dissection necessary for all patients with positive findings on sentinel lymph node biopsy? Validation of a breast cancer nomogram for predicting the likelihood of a non-sentinel lymph node. Tumori. 2009;95:153–5.PubMed
52.
go back to reference Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800–08.PubMedCrossRef Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800–08.PubMedCrossRef
Metadata
Title
Identifying Gaps in the Locoregional Management of Early Breast Cancer: Highlights from the Kyoto Consensus Conference
Authors
Masakazu Toi, MD
Eric P. Winer, MD
Takashi Inamoto, MD
John R. Benson, MD
John F. Forbes, MD
Michihide Mitsumori, MD
John F. R. Robertson, MD
Hironobu Sasano, MD
Gunter von Minckwitz, MD
Akira Yamauchi, MD
V. Suzanne Klimberg, MD
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-011-1666-7

Other articles of this Issue 10/2011

Annals of Surgical Oncology 10/2011 Go to the issue